Associate Professor of Pharmacy Practice, Full-time
B.S., Pharm.D., Arnold & Marie Schwartz College of Pharmacy and Health Sciences, LIU Pharmacy
DR. RODA PLAKOGIANNIS is an associate professor of pharmacy practice at the Arnold & Marie Schwartz College of Pharmacy since 2002. She received both her Bachelor of Science in Pharmacy and traditional Doctor of Pharmacy degrees from the Arnold & Marie Schwartz College of Pharmacy & Health Sciences. Dr. Plakogiannis completed an ASHP-accredited specialized pharmacy residency in primary care at the Bay Pines Veterans Medical Center in Tampa, Fl. She is a Board Certified Pharmacotherapy Specialist, a Diplomate and Fellow of the Accreditation Council for Clinical Lipidology and a Board Certified Clinical Lipid Specialist. She serves as one of the Board of Directors for the Northeastern Lipid Association and on the Accreditation Council for Clinical Lipidology Board of Governors. Dr. Plakogiannis also serves as the Adverse Drug Reactions Section Editor for the Journal of Pharmacy Practice.
Dr. Plakogiannis has presented on a national level in addition to local seminars. She has published numerous manuscripts and chapters in her field of expertise. She has been invited to serve as a consultant at the Aegerion and Amarin Lipid Pharmaceuticals Advisory Board meetings, to name a few.
Dr. Plakogiannis currently practices at NYU Langone Medical Center predominantly managing patients with hyperlipidemia, hypertension, anticoagulation and heart failure. Her scope of practice involves assessing ambulatory patients for medication-related problems, evaluating medication regimens to ensure that they are safe, appropriate, and cost-effective by identifying potential drug interactions, drug-related adverse effects, duplicate therapy, and obstacles/barriers to adherence. She also rounds with the Heart Failure Team at NYU to address medication related issues in hopes to decrease hospital readmissions.
Ambulatory care/ hyperlipidemia, hypertension, Chronic Heart Failure
Primary prevention of cardiovascular disease and treatment strategies in the management of hyperlipidemia, hypertension, heart failure, and transitions of care.
Plakogiannis, R. The National Lipid Association Recommendations for Patient Centered Management of Dyslipidemia: The Perfect Hybrid of NCEP ATP III, IAS, and 2013 ACC/AHA Guidelines? ACCP PRN Volume 8 Issue 11; 4-6.
Tanna, M. and Plakogiannis, R. The Impact of Hormonal Imbalance on Cardiovascular Health in Men: The Good, the Bad, and the Unknown. Lipid Spin 2015; 16-17.
Goriacko, P., Fazylov, R., Anderson, M., Plakogiannis R., “What is the Appropriate Duration of High-Dose Atorvastatin Therapy Post Acute Coronary Syndrome?” J Pharm Pract. 2014 Aug 8. pii: 0897190014544796. [Epub ahead of print]
Adly G, Plakogiannis, R., “Reinitiating Aspirin Therapy for Primary Prevention of Cardiovascular Events in a Patient Post Aspirin Induced Upper Gastrointestinal Bleed: A Case Report and Review of Literature.” Ann Pharmacother. 2013;47 (2): Epub 2013 Feb 5.
Plakogiannis R., Cioce L, Underberg J., “The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia.” Clin Investigation. 2012; 10;1033-1037.
Prlesi, L, Plakogiannis, R. Angioedema Resulting From NSAID and ACEI Coadministration: Case Report and Review of the Literature. Am J Health Syst Pharm. 2010 (67): 1351-1353.
Balas, M., Plakogiannis, R., Sinnett M. Periorbital Edema Associated with Separate Courses of Ibuprofen and Naproxen. Am J Health Syst Pharm. 2010 (67): 906-909.
Pham DQ, Nogid A, Plakogiannis R. Sitagliptin: A Novel Agent for the Management of Type 2 Diabetes. Am J Health Syst Pharm. 2008; 65:521-531.
Plakogiannis R, Cohen H. Is Evening Statin Administration Better for Optimal Low-Density Lipoprotein Cholesterol Lowering? Ann Pharmacother 2007;41:106-110.
Plakogiannis, R. and Nogid A. Acute Interstitial Nephritis Resulting From Vancomycin and Ceftriaxone Coadministration: Case Series and Review of the Literature. Pharmacotherapy. 2007;27(10):1456-1461.
Plakogiannis, R. and Ginzburg R. Possible Amiodarone-Warfarin Interaction: A Reemphasis on a Potentially Dangerous Drug - Drug Interaction. J of Pharm Practice 2007;20:469-473.
Plakogiannis R, Sakalis E. Compliance with the Seventh Report of the JNC 7 Guidelines and Blood Pressure Attainment in an Inner-City Tertiary Care Hospital. J Pharm Technol.2006; 22:86-90.
Plakogiannis R, Cohen H, Taft D. Effects of Morning Versus Evening Administration of Atorvastatin in Patients with Hyperlipidemia. Am J Health Syst Pharm. 2005; 62: 2491-2494.
Lieberman S, Plakogiannis R, Pham DQ. Diagnosis and Treatment of Venous Thromboembolic Diseases. Pharmacy Times. December 2006
Plakogiannis R. Understanding Warfarin Bioequivalency. Drug Store News Summer 2006. www.cedrugstorenews.com
Plakogiannis R, Rosenberg J, Nathan J. How are Insulin Glargine and Insulin Aspart Different from the ‘Older’ Insulins? Drug Topics Nov 2000; 41.
ASHP, Midyear Meeting, Anaheim, CA Dec 2014: Braverman D, Arafath S, Plakogiannis R. The Utilization of the JNC-8 Report and the 2013 ACC/AHA Guidelines Among Pharmacists
NLA Scientific Sessions. Orlando, May 2014: Plakogiannis R, Underberg J. Supplementation of Vitamin E in a Patient with Abetalipoproteinemia.
ACCP Spring Practice and Research. Charlotte, April 26, 2010: Plakogiannis R., Prlesi L. Angioedema After NSAID Initiation in a Patient Stable on an ACEI.
ASHP, Midyear Meeting, Las Vegas, Dec. 7, 2007: Nogid A., Plakogiannis R. Case Report: Aeromonas veronii biovar sobria bacteremia despite antibiotic prophylaxis in a patient with digit replantation.
ACCP Spring Practice and Research. Memphis, April 23, 2007: Schicchi G, Plakogiannis R. Coadminstration of Isoniazid and Warfarin: An Unexpected Drug─ Drug Interaction.
NLA 2nd Annual Meeting. Boston, April 8, 2006: Underberg J, Plakogiannis R. Establishing a HMG-CoA Reductase Inhibitor (Statin) Protocol for Informed Consent in Women of Childbearing Age.
ASHP, Midyear Meeting, Las Vegas, Dec. 7, 2005: Plakogiannis R, Nogid A. Case Report: Ceftriaxone - Induced Acute Interstitial Nephritis.
ISOPR 7th Annual European Congress, Hamburg, Germany. October 25, 2004: Poster Finalist Award in the Health Policy Studies Category. Plakogiannis R, Wong S. The Use of Internet-Based Technology to Assess Medication. Adherence in Patients with Hypertension and to Provide Interactive Health Information.
ASHP, Midyear Meeting, New Orleans, Dec. 7-10, 2003: Plakogiannis R. The Prevalence of White Coat HTN in the Primary Care Sector.
ACCP Spring Practice and Research Forum, Savannah GA, April 7-10, 2002: Plakogiannis R, Reilly J., Cohen H, Taft D. The Chronobiologic Effects of Atorvastatin: Morning Versus Evening Administration in Hyperlipidemic Adults.
Pharmacist’s Guide to Lipid Management (2nd edition) Chapter 6. Emerging Therapies for the Management of Lipid Abnormalities. Page 122-139.
Primary Care (2nd edition) Chapter 10. Dyslipidemias.
Pfizer Laboratory Research grant for $5,000 after the completion of Use of AdhereRx to enhance patient medication adherence
2014 David Newton Award for Excellence in Teaching
Cambridge Who’s Who Among Professional Pharmacists “Honors Edition” 2006/2007
ISOPR 7th Annual European Congress-Poster Finalist Award in the Health Policy Studies Category
Other Professional Activities
Aegerion Pharmaceuticals Advisory Board Meeting, New York City (October 2012)
Amarin Lipid Advisory Meeting, New York City (August 2012)
Science Research Manager Publicis Healthcare Communications Group (2008)
Value of Medicines Regional Speaker Meeting, Boston. MA, (June 2004)
Clinical Advisory Meeting: Update on Hypertension: Research and Guidelines: Uncovering the Relevant Data for Clinical Pharmacists, Scottsdale. AZ, (October 2003)
Member of The National Lipid Association (NLA)
Member of The American College of Clinical Pharmacy (ACCP)
Member of The American Society of Health-Systems Pharmacists (ASHP)
Member of The American Association of Colleges of Pharmacy (AACP)
Member of The American Pharmaceutical Association (APhA)
Member of The New York State Journal of Health System Pharmacy (NYSCHP)